Galapagos NV taps Landmark Bio for CAR-T therapy production
Landmark Bio has entered into a pivotal strategic manufacturing agreement with Galapagos NV, signaling a notable advance in the field of genomic medicines. This multi-year ... Read More
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission ... Read More
Novartis secures global rights to atopic dermatitis drug MOR106
In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive ... Read More